Antidiabetic
Phase 2Small molecule
Antidiabetic is one of 118 small molecule programs targeting Heart Failure. It is currently in Phase 2.
3
Indications
6
Total Trials
2
Active Trials
117
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
206 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerPreclinical
Brethine
SanofiPreclinical
Medrol
PfizerPreclinical
Amidate
PfizerPreclinical
Antidiabetic
FFederico II University
Phase 2
Activase
RochePreclinical
Zemplar
AbbViePreclinical
Adriamycin
PfizerPreclinical
Savaysa
Daiichi SankyoPreclinical
Xifaxan
SSalix
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diabetic Nephropathy2 trials
Magnesium Supplementation in Diabetic Nephropathy
Completed·—·Phase 2·NCT03824379·60 enrolled
Non-Alcoholic Fatty Liver Disease1 trial
Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients
Completed·—·Phase 2·NCT03850886·61 enrolled
Osteoarthritis1 trial
GLP1 Analogues and the Risk of Osteoarthritis
Not yet recruiting·—··NCT07360457·390 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Antidiabetic. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- FFederico II University